| Literature DB >> 30328947 |
Pattara Rattanawong1, Narut Prasitlumkum1, Tanawan Riangwiwat1, Napatt Kanjanahattakij2, Wasawat Vutthikraivit3, Pakawat Chongsathidkiet4, Ross J Simpson5.
Abstract
BACKGROUND: Recent studies suggest that baseline prolonged PR interval is associated with worse outcome in cardiac resynchronization therapy (CRT). However, a systematic review and meta-analysis of the literature have not been made.Entities:
Mesh:
Year: 2018 PMID: 30328947 PMCID: PMC6248241 DOI: 10.5935/abc.20180198
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Figure 1Search methodology and selection process.
The clinical characteristics and summary of the included studies
| First author | Freidman | Januszkiewicz | Kronborg | Olshansky | Lee | Rickard |
|---|---|---|---|---|---|---|
| Country of Origin | USA | USA | Denmark | USA | USA | USA |
| Year | 2016 | 2015 | 2010 | 2012 | 2014 | 2017 |
| Study type | Retrospective cohort study | Retrospective cohort study | Retrospective cohort study | Retrospective cohort study | Retrospective cohort study | Retrospective cohort study |
| Participants description | Patients who underwent CRT (LVEF ≤ 35 and QRS ≥ 120) | Patients who underwent CRT (LVEF ≤ 35%, QRS > 120, NYHA III, IV) | Patients who underwent CRT | Patients who underwent CRT (LVEF ≤ 35, QRS ≥ 120 and NYHA III, IV) | Patients who underwent CRT (LVEF ≤ 35, QRS ≥ 120 and NYHA III, IV) | Patients who underwent CRT (LVEF ≤ 35, QRS ≥ 120) |
| Median duration of follow up (Months) | 34 | 30.1 | 30 | 15.95 | 52.4 | 61.2 |
| Definition of prolonged PR | ≥ 230 ms | ≥ 200 ms | ≥ 200 ms | ≥ 200 ms | ≥ 200 ms | ≥ 200 ms |
| Number of patients with prolonged PR | 2906 | 125 | 208 | 638 | 204 | 197 |
| Number of patients with not prolonged PR | 15994 | 158 | 232 | 574 | 199 | 275 |
| Mean age of patients | 75.37 | 66.00 | 66.00 | 65.56 | 66.72 | 65.10 |
| confounder adjustment | age, race, QRS, Intraventricular conduction, Non ischemic cardiomyopathy, NYHA, HF duration, eGFR, BUN, SBP | sex, RBBB, Ischemic cardiomyopathy, AF, medications | age, sex, HF aetiology, NYHA, DM, AF, ICD, LVEF | age, sex, NYHA, LVEF, LBBB, QRS, HR, SBP, DBP, ischemic status, comorbidities, medication | age, sex, ischemic cardiomyopathy, RV size, RV dysfunction, NYHA, MR grade, PASP, medication | age, sex, ischemic cardiomyopathy, LVEF, QRS, LBBB, Cr, NYHA |
AF: atrial fibrillation; BUN: blood urea nitrogen; HF: heart failure; Cr: creatinine; CRT: cardiac resynchronization therapy; DM: diabetes mellitus; DBP: diastolic blood pressure; eGFR : estimated Glomerular infiltration; HR: heart rate; ICD: implanted cardiac defibrillator; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NYHA: New York Heart Association; PASP: pulmonary artery systolic pressure; RBBB: right bundle branch block; RV: right ventricular; SBP: systolic blood pressure.
Newcastle–Ottawa scales of the included studies
| Study | selection | comparability | outcome | ||||||
|---|---|---|---|---|---|---|---|---|---|
| representativeness | selection of the non-exposed cohort | ascertainment | end point not present at start | Comparability (confounding) | assesment of outcome | follow up duration | adequacy follow-up | total | |
| Freidman | * | * | * | * | ** | * | * | * | 9 |
| Januszkiewicz | * | * | * | * | ** | * | * | * | 9 |
| Kronborg | * | * | * | * | ** | * | * | * | 9 |
| Olshansky | * | * | * | * | ** | * | * | 8 | |
| Ying-Hsiang | * | * | * | * | ** | * | * | * | 9 |
| Rickard | * | * | * | * | ** | * | * | * | 9 |
Intra-study risks of bias of included studies
| Study | Clear definition of study population? | Clear definition of outcomes and assessment? | Independent assessment of outcomes? (e.g. by third party) | Sufficient Follow-up duration? | Selective loss during Follow-up? | Limitations identified? |
|---|---|---|---|---|---|---|
| Freidman | Yes | Yes | Yes | Yes | No | Yes |
| Januszkiewicz | Yes | Yes | No | Yes | No | Yes |
| Kronborg | Yes | Yes | Yes | Yes | No | Yes |
| Kutyifa | Yes | Yes | Yes | Yes | No | No |
| Olshansky | No | Yes | Yes | No | No | Yes |
| Ying-Hsiang | Yes | Yes | No | Yes | No | Yes |
Figure 2Forest plot of the included studies assessing the association between prolonged PR and risk of all-cause mortality (2A), HF hospitalization (2B), and composite outcome (2C).
Figure 3Funnel plot of prolonged PR and risk of all-cause mortality (3A), HF hospitalization (3B), and composite outcome (3C). Circles represent the observed published studies.